Strong 2025 fundamentals with 23% AUM growth, 25% fee-related earnings growth, record $51B capital raise, and 31% compound EPS growth rate. Current 40% stock decline appears disconnected from underlying business performance, creating attractive entry point with 5.5% dividend yield and analyst consensus price target of $64.
TPG's participation in this significant acquisition shows active deal-making and strategic investment in the healthcare industry alongside a top-tier partner.
Articles that tag TPG but are mainly about other companies.
Mentioned as a bidder in the student housing deal, but no substantive commentary or performance context provided.
Stock showed minimal movement (+0.65%) despite being mentioned among companies impacted by Blue Owl's private credit issues, suggesting market differentiation.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
